Genital warts and HPV vaccination

Česká verzia

Authors: R. Pilka ¹; V. Dvořák ²; Tomáš Fait ³
Authors place of work: Porodnicko-gynekologická klinika, LF UP a FN, Olomouc, přednosta prof. MUDr. R. Pilka, Ph. D. ¹; Centrum ambulantní gynekologie a primární péče, Brno, vedoucí lékař MUDr. V. Dvořák ²; Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. A. Martan, DrSc. ³
Published in the journal: Ceska Gynekol 2011; 76(6): 468-470
Category: Original Article

Summary

Objective:
To present and overview of incidence of, and cost of care for, genital warts.

Subject:
Review.

Setting:
Department of Obstetrics and Gynecology, Palacky University and Faculty University, Olomouc; Office gynecology and primary care centre, Brno; Department of Obstetrics and Gynecology, Charles university in Prague-First Faculty of Medicine and General Faculty Hospital, Prague.

Method:
Literature review of incidence of, and cost of care for, genital warts in some european countries, North America and Australia.

Conclusion:
Genital warts exert a considerable impact on health services, a large proportion of which could be prevented through immunisation using the quadrivalent human papillomavirus vaccine.

Key words:
HPV infection, HPV vaccination, genital warts.

Zdroje

1. World Health Organization. Human papillomavirus infection and cervical cancer, in www.who.int/vaccine_research/diseases/ hpv/en/, 2004.

2. Ault, K A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet, 2007, 369, p. 1861‑1868.

3. Cassell, JA., Mercer, CH., Sutcliffe, L., et al. Trends in sexually transmitted infections in general practice 1990-2000: population based study using data from the UK general practice research database. BMJ, 2006, 332, p. 332-334.

4. Castellsague, X., Cohet, C., Puig-Tintore, LM., et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health, 2009, 19, p. 106-110.

5. Clarke, P., Ebel, C., Catotti, DN., et al. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS, 1996, 7, p. 197-200.

6. De Carvalho, N., Teixeira, J., Roteli-Martins, CM., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine, 2010, 28, p. 6247-6255.

7. Desai, S., Wetten, S., Woodhall, SC., et al. Genital warts and cost of care in England. Sex Transm Infect, 87, p. 464-468.

8. Dillner, J., Kjaer, SK., Wheeler, CM., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 2010, 341, p. c3493.

9. Donovan, B., Franklin, N., Guy, R., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis, 11, p. 39-44.

10. Fairley, CK., Hocking, JS., Gurrin, LC., et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect, 2009, 85, p. 499-502.

11. Ferlay, J., Bray, F., Pisani, P., Parin, DM. Cancer incidence, mortality and prevalence worldwide, in Globocan 2002, IARCPress, Ed., 2004.

12. Hillemanns, P., Breugelmans, JG., Gieseking, F., et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis, 2008, 8, p. 76.

13. Hoy, T., Singhal, PK., Willey, VJ., et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin, 2009, 25, p. 2343-2351.

14. Insinga, RP., Dasbach, EJ., Myers, ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis, 2003, 36, p. 1397-1403.

15. Langley, PC., White, DJ., Drake, SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS, 2004, 15, p. 501-508.

16. Lukasiewicz, E., Aractingi, S. , Flahault, A. [Incidence and management of condylomata acuminata by French general physicians]. Ann Dermatol Venereol, 2002, 129, p. 991-996.

17. Marra, F., Ogilvie, G., Colley, L., et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect, 2009, 85, p. 111-115.

18. Maw, RD., Reitano, M., Roy, M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS, 1998, 9, p. 571-578.

19. Monsonego, J., Breugelmans, JG., Bouee, S., et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil, 2007, 35, p. 107-113.

20. Pirotta, M., Stein, AN., Conway, EL., et al. Genital warts incidence and healthcare resource utilisation in Australia, Sex Transm Infect, 86, p. 181-186.